Ceretine™: The Superior Nicotine Alternative

Everything you need to know about Ceretine™

What is Ceretine™?

How is Ceretine™ made?

Clinical Validation

Receptor Binding Study

We investigated the relative nAChR activation potential of Nicotinic α4, α3, and α6 using an agonist Fluorometric Imaging Plate Reader (FLIPR) assay.

nAChr Activation Study - α4

Nicotinic α4 receptors have high affinity for nicotine and account for >90% of nicotine binding to brain tissue.

nAChR Activation Study - α3

Nicotinic α3 receptors are involved in nicotine reward and physical withdrawal.

nACHr Activation Study - α6

Nicotinic α6 receptors are involved in nicotine-stimulated dopamine release and may play a role in nicotine dependence.

How was Ceretine™ developed?

Planned Studies:

FAQs